Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia

Pharmacogenomics

Volumn 14, Issue 16, 2013, Pages 2013-2021

  Sorich, Michael J ^a,b   Horowitz, John D ^c   Sorich, Wassana ^d   Wiese, Michael D ^a   Pekarsky, Brita ^e   Karnon, Jonathan D ^c  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d REPATRIATION GENERAL HOSPITAL   (Australia)

^e BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

clopidogrel; cost effectiveness; cytochrome P450 2C19; genotype; pharmacogenetics

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; TICAGRELOR;

ACUTE CORONARY SYNDROME; ALLELE; ARTICLE; AUSTRALIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYP2C19 GENE; DRUG CHOICE; DRUG EFFICACY; GENOTYPE; HUMAN; PHARMACOGENETICS; QUALITY ADJUSTED LIFE YEAR;

ACUTE CORONARY SYNDROME; ADENOSINE; ALLELES; ARYL HYDROCARBON HYDROXYLASES; AUSTRALIA; COST-BENEFIT ANALYSIS; GENOTYPE; HUMANS; MARKOV CHAINS; TICLOPIDINE;

EID: 84889055569     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.164     Document Type: Article

References (28)

1. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045-1057 (2009).
2. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001-2015 (2007).
3. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306(24), 2704-2714 (2011).
4. Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16), 1821-1830 (2010).
5. Sorich MJ, Polasek TM, Wiese MD. Challenges and limitations in interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics. Clin. Pharmacol. Ther. 94(3), 376-382 (2013).
6. Mega JL, Topol EJ, Sabatine MS. CYP2C19 genotype and cardiovascular events. JAMA 307(14), 1482-1485 (2012).
7. Zabalza M, Subirana I, Sala J et al. Meta-analyses of the association between cytochrome CYP2C19 loss-and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 98(2), 100-108 (2012).
8. Sorich MJ, Polasek TM, Wiese MD. Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. Thromb. Haemost. 108(1), 199-200 (2012).
9. Wallentin L, James S, Storey RF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749), 1320-1328 (2010).
10. Wallentin L. Genetic substudy of the PLATO trial-authors' reply. Lancet 377(9766), 637-638 (2011).
11. Nikolic E, Janzon M, Hauch O, Wallentin L, Henriksson M. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. Eur. Heart J. 34(3), 220-228 (2013).
12. Crespin DJ, Federspiel JJ, Biddle AK, Jonas DE, Rossi JS. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. Value Health 14(4), 483-491 (2011).
13. Reese ES, Mullins CD, Beitelshees AL, Onukwugha E. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy 32(4), 323-332 (2012).
14. Panattoni L, Brown PM, Te Ao B, Webster M, Gladding P. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation. Pharmacoeconomics 30(11), 1067-1084 (2012).
15. Sorich MJ, Coory M, Pekarsky BAK. Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups. PLoS ONE 8(8), e72256 (2013).
16. Johnson JA, Roden DM, Lesko LJ, Ashley E, Klein TE, Shuldiner AR. Clopidogrel: a case for indication-specific pharmacogenetics. Clin. Pharmacol. Ther. 91(5), 774-776 (2012).
17. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494-502 (2001).
18. Sorich MJ, McKinnon RA. Personalized medicine: potential, barriers and contemporary issues. Curr. Drug Metab. 13(7), 1000-1006 (2012).
19. Song F, Xiong T, Parekh-Bhurke S et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ 343, d4909 (2011).
20. Mehta SR, Tanguay JF, Eikelboom JW et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376(9748), 1233-1243 (2010).
21. Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J. Thromb. Haemost. 8(8), 1678-1684 (2010).
22. Mega JL, Close SL, Wiviott SD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009).
23. Mega JL, Close SL, Wiviott SD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19), 2553-2560 (2009).
24. Cannon CP, Harrington RA, James S et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 375(9711), 283-293 (2010).
25. Lu CY, Karnon J, Sorich MJ. The importance of high-quality evidence of the long-term impact of nonfatal events used in randomized controlled trials: a case study of prasugrel. Clin. Pharmacol. Ther. 90(1), 27-29 (2011).
26. Cadilhac DA, Carter R, Thrift AG, Dewey HM. Estimating the long-term costs of ischemic and hemorrhagic stroke for Australia. Stroke 40(3), 915-921 (2009).
27. Clarke P, Leal J, Kelman C, Smith M, Colagiuri S. Estimating the cost of complications of diabetes in Australia using administrative health-care data. Value Health 11(2), 199-206 (2008).
28. Hurley SF, Matthews JP. The quit benefits model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking. Cost Eff. Resour. Alloc. 5, 2 (2007).